{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:15:43Z","timestamp":1792782943018,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82270711"],"award-info":[{"award-number":["No.82270711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei Province Major Scientific and Technological Special Project","award":["No. 2019ACA137"],"award-info":[{"award-number":["No. 2019ACA137"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01829-2","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T04:33:58Z","timestamp":1754886838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study"],"prefix":"10.1007","volume":"25","author":[{"given":"Huapan","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-146X","authenticated-orcid":false,"given":"Xinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"1","key":"1829_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390(1):20\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2305635.","journal-title":"N Engl J Med"},{"issue":"10","key":"1829_CR2","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","volume":"38","author":"CJ Willey","year":"2023","unstructured":"Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023;38(10):2340\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfad082.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1829_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429\u201341. https:\/\/doi.org\/10.1053\/j.ajkd.2021.01.024.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1829_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1): 67. https:\/\/doi.org\/10.1038\/s41572-023-00476-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"1829_CR5","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888\u201398. https:\/\/doi.org\/10.1001\/jama.2022.5368.","journal-title":"JAMA"},{"issue":"10","key":"1829_CR6","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","volume":"5","author":"J Barratt","year":"2020","unstructured":"Barratt J, Rovin BH, Cattran D, et al. Why target the gut to treat IgA nephropathy? Kidney Int Rep. 2020;5(10):1620\u20134. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.009.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"1829_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","volume":"33","author":"SC Yeo","year":"2018","unstructured":"Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018;33(5):763\u201377. https:\/\/doi.org\/10.1007\/s00467-017-3699-z.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"1829_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/asn.2016050496","volume":"28","author":"M Muto","year":"2017","unstructured":"Muto M, Manfroi B, Suzuki H, et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J Am Soc Nephrol. 2017;28(4):1227\u201338. https:\/\/doi.org\/10.1681\/asn.2016050496.","journal-title":"J Am Soc Nephrol"},{"key":"1829_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169084","volume":"14","author":"J Cai","year":"2023","unstructured":"Cai J, Gao D, Liu D, Liu Z. Telitacicept for autoimmune nephropathy. Front Immunol. 2023;14: 1169084. https:\/\/doi.org\/10.3389\/fimmu.2023.1169084.","journal-title":"Front Immunol"},{"issue":"1","key":"1829_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/asn.0000000000000242","volume":"35","author":"K El Karoui","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024;35(1):103\u201316. https:\/\/doi.org\/10.1681\/asn.0000000000000242.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1829_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"10388","key":"1829_CR12","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/s0140-6736(23)00569-x","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(23)00569-x.","journal-title":"Lancet"},{"issue":"1","key":"1829_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01320-2","volume":"28","author":"L Wu","year":"2023","unstructured":"Wu L, Du X, Lu X. Role of telitacicept in the treatment of IgA nephropathy. Eur J Med Res. 2023;28(1): 369. https:\/\/doi.org\/10.1186\/s40001-023-01320-2.","journal-title":"Eur J Med Res"},{"issue":"3","key":"1829_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014.","journal-title":"Kidney Int Rep"},{"key":"1829_CR15","doi-asserted-by":"publisher","unstructured":"Fujihara CK, I DELN, Malheiros D, Antunes GR, IB DEO, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol. 2000;11(2):283\u2013290. https:\/\/doi.org\/10.1681\/asn.V112283","DOI":"10.1681\/asn.V112283"},{"issue":"2","key":"1829_CR16","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2023","unstructured":"Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54054.","journal-title":"JAMA Netw Open"},{"key":"1829_CR17","doi-asserted-by":"publisher","unstructured":"KDIGO 2024 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2024;105(4s):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"5","key":"1829_CR18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014\u201321. https:\/\/doi.org\/10.1016\/j.kint.2017.02.003.","journal-title":"Kidney Int"},{"issue":"5","key":"1829_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534\u201345. https:\/\/doi.org\/10.1038\/ki.2009.243.","journal-title":"Kidney Int"},{"key":"1829_CR20","doi-asserted-by":"publisher","first-page":"204062231988787","DOI":"10.1177\/2040622319887875","volume":"10","author":"L Wang","year":"2019","unstructured":"Wang L, Ren D, Huang T, Liu X, Xu G. The effectiveness and safety of full-dose versus half-dose corticosteroid plus renin-angiotensin system blockers for IgA nephropathy. Ther Adv Chronic Dis. 2019;10:2040622319887875. https:\/\/doi.org\/10.1177\/2040622319887875.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"1829_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69(6):788\u201395. https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.027.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1829_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan J, Cattran DC. The kdigo practice guideline on glomerulonephritis: reading between the (guide)lines\u2013application to the individual patient. Kidney Int. 2012;82(8):840\u201356. https:\/\/doi.org\/10.1038\/ki.2012.280.","journal-title":"Kidney Int"},{"issue":"2","key":"1829_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176\u201394. https:\/\/doi.org\/10.1016\/j.amjms.2020.10.003.","journal-title":"Am J Med Sci"},{"issue":"25","key":"1829_CR24","doi-asserted-by":"publisher","first-page":"11462","DOI":"10.7150\/thno.49778","volume":"10","author":"JW He","year":"2020","unstructured":"He JW, Zhou XJ, Lv JC, Zhang H. Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies. Theranostics. 2020;10(25):11462\u201378. https:\/\/doi.org\/10.7150\/thno.49778.","journal-title":"Theranostics"},{"key":"1829_CR25","doi-asserted-by":"publisher","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):S1-s276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"4","key":"1829_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479\u201385. https:\/\/doi.org\/10.1093\/ndt\/gfr527.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1829_CR27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ki.2014.63","volume":"86","author":"R Coppo","year":"2014","unstructured":"Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828\u201336. https:\/\/doi.org\/10.1038\/ki.2014.63.","journal-title":"Kidney Int"},{"issue":"6","key":"1829_CR28","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306\u201315. https:\/\/doi.org\/10.1016\/j.kint.2024.03.012.","journal-title":"Kidney Int"},{"key":"1829_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/antib12020040","author":"D Petrou","year":"2023","unstructured":"Petrou D, Kalogeropoulos P, Liapis G, Lionaki S. IgA nephropathy: current treatment and new insights. Antibodies. 2023. https:\/\/doi.org\/10.3390\/antib12020040.","journal-title":"Antibodies"},{"issue":"7","key":"1829_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0044","volume":"85","author":"B Ellison","year":"2024","unstructured":"Ellison B, Cader R, Willcocks L. Advances in primary glomerulonephritis. Br J Hosp Med (Lond). 2024;85(7):1\u201311. https:\/\/doi.org\/10.12968\/hmed.2024.0044.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"4","key":"1829_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387. https:\/\/doi.org\/10.1136\/ard-2023-224854.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1829_CR32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","volume":"9","author":"J Zan","year":"2024","unstructured":"Zan J, Liu L, Li G, et al. Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy. Kidney Int Rep. 2024;9(4):1067\u201371. https:\/\/doi.org\/10.1016\/j.ekir.2024.01.003.","journal-title":"Kidney Int Rep"},{"issue":"Suppl 2","key":"1829_CR33","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","volume":"16","author":"SC Yeo","year":"2023","unstructured":"Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii9\u201318. https:\/\/doi.org\/10.1093\/ckj\/sfad200.","journal-title":"Clin Kidney J"},{"issue":"2","key":"1829_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","volume":"84","author":"C Tang","year":"2024","unstructured":"Tang C, Chen P, Si FL, et al. Time-varying proteinuria and progression of IgA Nephropathy: a cohort study. Am J Kidney Dis. 2024;84(2):170-178.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2023.12.016.","journal-title":"Am J Kidney Dis"},{"issue":"1 Pt 2","key":"1829_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1399-0012.1996.tb00651.x","volume":"10","author":"AC Allison","year":"1996","unstructured":"Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996;10(1 Pt 2):77\u201384.","journal-title":"Clin Transplant"},{"key":"1829_CR36","unstructured":"Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. 2002;82(12):796\u2013801."},{"issue":"2","key":"1829_CR37","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","volume":"68","author":"S Tang","year":"2005","unstructured":"Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68(2):802\u201312. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00460.x.","journal-title":"Kidney Int"},{"issue":"10","key":"1829_CR38","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/asn.2017010108","volume":"28","author":"AM Sevillano","year":"2017","unstructured":"Sevillano AM, Guti\u00e9rrez E, Yuste C, et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089\u201399. https:\/\/doi.org\/10.1681\/asn.2017010108.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1829_CR39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.ajkd.2022.02.022","volume":"80","author":"MK Saha","year":"2022","unstructured":"Saha MK, Massicotte-Azarniouch D, Reynolds ML, et al. Glomerular hematuria and the utility of urine microscopy: a review. Am J Kidney Dis. 2022;80(3):383\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2022.02.022.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1829_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","volume":"76","author":"GZ Yu","year":"2020","unstructured":"Yu GZ, Guo L, Dong JF, et al. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis. 2020;76(1):90\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2019.11.008.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"1829_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10157-022-02226-9","volume":"26","author":"M Toda","year":"2022","unstructured":"Toda M, Kume A, Hara M, et al. Efficacy and limitations of additional steroid pulse therapy in IgA nephropathy patients whose hematuria did not remit on tonsillectomy and protocol steroid pulse therapy. Clin Exp Nephrol. 2022;26(9):859\u201366. https:\/\/doi.org\/10.1007\/s10157-022-02226-9.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1829_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12882-022-02791-x","volume":"23","author":"S Yamatani","year":"2022","unstructured":"Yamatani S, Kono K, Fujii H, et al. Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study. BMC Nephrol. 2022;23(1):153. https:\/\/doi.org\/10.1186\/s12882-022-02791-x.","journal-title":"BMC Nephrol"},{"issue":"10","key":"1829_CR43","doi-asserted-by":"publisher","first-page":"100534","DOI":"10.1016\/j.xkme.2022.100534","volume":"4","author":"D Samsonov","year":"2022","unstructured":"Samsonov D, Zolotnitskaya A, Matloff R, Pereira T, Solomon S. Mycophenolate mofetil for severe IgA vasculitis nephropathy in children: an observational study. Kidney Med. 2022;4(10):100534. https:\/\/doi.org\/10.1016\/j.xkme.2022.100534.","journal-title":"Kidney Med"},{"issue":"2","key":"1829_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5301\/jn.2011.8452","volume":"25","author":"D Roccatello","year":"2012","unstructured":"Roccatello D, Rossi D, Marletto F, et al. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. J Nephrol. 2012;25(2):198\u2013203. https:\/\/doi.org\/10.5301\/jn.2011.8452.","journal-title":"J Nephrol"},{"issue":"6","key":"1829_CR45","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.asn.0000068460.37369.dc","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, Morales E, Hern\u00e1ndez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578\u201383. https:\/\/doi.org\/10.1097\/01.asn.0000068460.37369.dc.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1829_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324. https:\/\/doi.org\/10.1016\/j.kint.2021.03.033.","journal-title":"Kidney Int"},{"issue":"2","key":"1829_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391\u2013402. https:\/\/doi.org\/10.1016\/j.kint.2022.09.017.","journal-title":"Kidney Int"},{"issue":"1","key":"1829_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang YZ, Shi SF, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74(1):15\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.026.","journal-title":"Am J Kidney Dis"},{"key":"1829_CR49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409415","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409415.","journal-title":"N Engl J Med"},{"issue":"4","key":"1829_CR50","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/asn.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306\u201313. https:\/\/doi.org\/10.1681\/asn.2016060640.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1829_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","volume":"105","author":"H Zhang","year":"2024","unstructured":"Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024;105(1):189\u201399. https:\/\/doi.org\/10.1016\/j.kint.2023.09.027.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01829-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01829-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01829-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:25Z","timestamp":1764917365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01829-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01829-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6836894\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol has been approved by Wuhan University of Renmin Hospital Independent Ethics Committee for clinical research and animals (2024K-K266). This study was carried out according to the Declaration of Helsinki. All patients involved in this study were informed, and the informed consents were obtained from all participants before treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"287"}}